This study is for patients that have been diagnosed with advanced small cell lung cancer. The investigational drug in this study is Nivolumab (OPDIVO). The purpose of this study is to compare any good and bad effects of using nivolumab along with the usual chemotherapy regimen of cisplatin/carboplatin and etopiside to using the usual chemotherapy approach alone. Participants can expect to be in this study receiving drug and chemotherapy for up to a month with follow up for up to 5 years.
The primary purpose of this study is to evaluate stigma among lung cancer survivors in the state of South Carolina. To address this purpose, the principal investigator will evaluate stigma utilizing Cataldo's Lung Cancer Stigma Scale (CLCSS) and compare the findings with variables of depression and quality of life. The CLCSS will also be assessed for readability and acceptability among African American lung cancer survivors since this has not been evaluated in this particular population prior to this study.
This study is for patients that have been diagnosed with mesothelioma. This study is to test whether giving one drug, atezolizumab, along with cisplatin and pemetrexed, before surgery and atezolizumab after surgery by vein is safe. Atezolizumab is the experimental cancer drug in this study, which has already been approved for the treatment of patients with bladder cancer and lung cancer. Participants can expect to be in this study for up to a year and followed for side effect for up to three years after study completion.
To test the efficacy, safety and neurocognitive outcomes of advanced NSCLC patients, following stereotactic radiosurgery (SRS) for 1 inoperable brain metastasis or 2-10 brain metastases, treated with NovoTTF-100M and supportive treatment compared to supportive treatment alone.
Participants will be randomized to the Supportive Care Group and will receive radiosurgery followed by supportive care, or to the NovoTTF-110M group who will receive radiosurgery then begin using the study device with supportive care. The device is to be worn at least 18 hours every day. There is a provision for those randomized to the supportive care arm to crossover to the study device after tumor has recurred twice. All participants will be seen every 8 weeks in the clinic until they progress a second time. Once study treatment is terminated, they will return to the clinic 8 weeks following the last visit, then be contacted once per month by telephone.
The primary objective of this study is to develop a blood-based gene expression signature, known as the ONC-LN-04 Lung Test, to be used in the detection of lung cancer in patients who underwent radiologic screening for lung cancer and had lung nodules detected. We intend to enroll volunteers who are being evaluated by a Ralph H. Johnson VAMC pulmonologist as part of their standard medical care. Participants will be current or former smokers, who have either (a) radiologic evidence of lung nodules, or (b) a confirmed diagnosis of non-small cell lung cancer (NSCLC) and has not undergone surgical excision, chemotherapy or radiation therapy for this malignancy. A single blood sample will be obtained from willing participants, then stored and analyzed for measurement of gene expression and development of the ONC-LN-04 test. Active participation in this study will be over once a blood sample is obtained; however, we may need access to participants' medical records post-enrollment and sample collection in order to monitor medical outcomes. Review of participants' medical records will occur until up to approximately 3,500 subjects have been enrolled and have provided clinical information and a blood sample.
This study is for patients who have been diagnosed with advanced or metastatic non-small cell lung cancer (NSCLC) whose disease improved or remained unchanged after receiving nivolumab or pembrolizumab and whose disease has now worsened. The investigational drug in this study is called ALT-803. Participants can expect to receive the study drug ALT-803 in combination with an approved drug called pembrolizumab or they will receive ALT-803 in combination with an approved drug called nivolumab. Participants will receive ALT-803 in combination with pembrolizumab if they have previously received pembrolizumab. They will receive ALT-803 in combination with nivolumab if they have previously received nivolumab. The purpose of this research study is to test the effectiveness of the study drug, ALT-803, in combination with either pembrolizumab or nivolumab in patients with advanced or metastatic NSCLC that initially had improvement or no change in disease after receiving pembrolizumab or nivolumab and who now have disease worsening. Participation in this study should take approximately 24 months.
Screening for lung cancer at earlier, more treatable stages has the potential to reduce mortality from the U.S.'s most deadly cancer. Annual lung cancer screening with low-dose computed tomography is now recommended for high risk individuals based on age and smoking history. This study will evaluate a smoking cessation intervention for lung cancer screening patients. We will evaluate quit rates after a standard intervention (brief counseling session at time of LCS) versus a medication and text messaging intervention.
This study is for patients who have been diagnosed with extensive-stage small cell lung cancer (SCLC). This study is being conducted to test whether or not rovalpituzumab tesirine (SC16LD6.5) combined with nivolumab alone or with nivolumab and ipilimumab are useful treatments for small cell lung cancer, after at least one prior treatment has failed.The investigational drugs in this study are Rovalpituzumab Tesirine (SC16LD6.5), Nivolumab (BMS-936558, MDX1106, ONO-4538, Opdivo®), and Ipilimumab (MDX-010, Yervoy®) . If participants agree to take part in this study, their involvement will last for as long as their study doctor confirms their cancer is not getting worse and there have been no significant side effects. There is no limit to the number of cycles of study treatment participants can receive.
Although the five-year survival rate of people diagnosed with lung cancer is increasing, excessive symptom burden during the period of survivorship remains a prevalent and complex problem for survivors and their family members. The growing number of lung cancer survivors warrants the development of innovative and unique evidence-based intervention programs designed to improve their health outcomes. This study, Breathe Easier, is lung cancer specific, targets multiple symptoms and lifestyle behaviors will test a mindfulness-based intervention that includes breathing retraining exercises, mindfulness-based meditation, yoga for varying skill levels, and participant interaction designed specifically to address issues of importance to survivors of lung cancer and their family members.
The main objective of this study is to better understand the biomarkers of patients who are candidates for lung cancer screening. Biomarkers are biologic substances found in the blood and may be related to lung disease risk and detection. We intend to enroll volunteers who are participating in a lung cancer screening program at the Ralph H. Johnson VA Medical Center and are being seen by a pulmonologist as part of their standard medical care.
Two blood samples will be obtained, 12 months apart, then stored and analyzed to better understand the biomarkers found in blood and to help develop and test blood based screening or diagnostic tests. Active participation in this study will be over once both blood samples are obtained. However, we may conduct medical chart reviews of some participants for up to 27 months in order to look at their medical outcomes.